DaVita Inc. (DVA)
NYSE: DVAHealth CareMisc Health and Biotechnology ServicesUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
DVA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $11.28B
- P/E (TTM)
- 14.93
- Forward P/E
- 10.31
- EPS (TTM)
- $11.84
- Dividend yield
- None
- 52-week range
- 101.00 – 247.49
- Day range
- 175.92 – 182.61
- Volume / Avg
- 650.29K / 776.03K
- Beta
- —
- Shares outstanding
- 63.80M
- Next earnings
- Nov 4, 2026
52-week range
DVA stock today
Shares of DaVita (DVA) finished lower on Oct 7 at $176.78, a drop of 2.01% or $3.62 per share, versus the S&P 500's 0.22% decline. Shares are 28.6% below their 52-week high of $247.49, set on Aug 3, 2026 and 75.0% above the 52-week low of $101.00, in the middle of the past year's range. DVA is up 55.6% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 34.9%.
At 14.9x trailing earnings, DaVita trades below the peer-group median of 28.0x. Its forward P/E of 10.3x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. DaVita's next earnings report is expected on Nov 4, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About DaVita
Company profileDaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers.
- Sector
- Health Care
- Industry
- Misc Health and Biotechnology Services
- CEO
- Mr. Javier J. Rodriguez
- Headquarters
- Denver, CO
- Employees
- 78,000
- Website
- davita.com
Financial highlights
Full financialsIn fiscal 2025, DaVita generated $13.64 billion in revenue, up 6.5% from fiscal 2024, its 3rd consecutive year of revenue growth. Net income was $746.8 million (-20.2% year over year), for a net margin of 5.5% versus a median of 6.7% in the prior 5 years. Operating margin was 15.0%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $13.64B | $12.82B | $12.14B | $11.61B | $11.62B |
| Growth | +6.46% | +5.56% | +4.57% | -0.08% | +0.59% |
| Net income | $746.80M | $936.34M | $691.53M | $560.40M | $978.45M |
| EPS (diluted) | $9.84 | $10.73 | $7.42 | $5.85 | $8.90 |
Analyst forecast
ForecastConsensus (8 analysts)
buy
Avg. price target
$219.86+24.37%
- Strong buy 0
- Buy 3
- Hold 4
- Sell 0
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 4, 2026
- EPS estimate
- $3.78
- Last reported (Q2 2026)
- Aug 4, 2026
- EPS actual vs est.
- $4.02 vs —
DVA news
All DVA newsDaVita peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| FMSFresenius Medical Care AG ADR | 20.69 | -7.72% | $11.01B | vs DVA |
| SHCSotera Health Company | 17.90 | -1.92% | $5.11B | vs DVA |
| PGNYProgyny Inc. | 27.55 | +6.33% | $2.11B | vs DVA |
| AGLagilon health inc. | 85.70 | +2.76% | $1.44B | vs DVA |
| VMDViemed Healthcare Inc. | 9.37 | +0.43% | $356.89M | vs DVA |
| PARKPark Dental Partners Inc. | 20.94 | +1.26% | $99.58M | vs DVA |
| CCELCryo-Cell International Inc. | 3.91 | +0.77% | $31.52M | vs DVA |
| MGRXMangoceuticals Inc. | 0.4437 | -1.40% | $9.57M | vs DVA |
Indexes, lists and sector
Index membership
DaVita stock FAQ
What is DaVita's stock price today?
DVA last traded at $176.78 as of Oct 7, 4:00 PM EDT, down 2.01% on the day. Prices are delayed at least 15 minutes.
Does DaVita pay a dividend?
No. DaVita does not currently pay a regular cash dividend.
When is DaVita's next earnings date?
DaVita is expected to report earnings on Wednesday, November 4, 2026. Analysts expect EPS of $3.78.
What is DVA's P/E ratio?
DVA trades at a trailing P/E ratio of 14.93 and a forward P/E of 10.31, compared with a median of 28.0 for its closest peers.
Is DaVita in the S&P 500?
Yes. DaVita (DVA) is a constituent of the S&P 500 index.
Who is DaVita's CEO?
Mr. Javier J. Rodriguez is the chief executive officer of DaVita Inc., which has about 78,000 employees.
Has DVA ever split its stock?
Yes. The most recent DVA stock split was a 2-for-1 split on Sep 9, 2013, one of 3 splits on record.